Hospira Management Discusses Q2 2012 Results - Earnings Call Transcript

Hospira (HSP)

Q2 2012 Earnings Call

August 01, 2012 9:00 am ET

Executives

Karen King

F. Michael Ball - Chief Executive Officer, Director and Member of Science, Technology & Quality Committee

Thomas E. Werner - Chief Financial Officer and Senior Vice President of Finance

Sumant Ramachandra - Chief Scientific Officer and Senior Vice President of R&D, Medical & Regulatory

Analysts

David H. Roman - Goldman Sachs Group Inc., Research Division

Aaron Gal - Sanford C. Bernstein & Co., LLC., Research Division

John M. Putnam - Capstone Investments, Research Division

Ami Fadia - UBS Investment Bank, Research Division

Matthew Taylor - Barclays Capital, Research Division

Marshall Urist - Morgan Stanley, Research Division

Gregory B. Gilbert - BofA Merrill Lynch, Research Division

Shibani Malhotra - RBC Capital Markets, LLC, Research Division

Presentation

Operator

Welcome to Hospira's Second Quarter 2012 Conference Call. [Operator Instructions] I will now turn the call over to Karen King, Vice President of Investor Relations. Karen, you may now begin your conference.

Karen King

Thank you. Good morning, everyone, and welcome to our second quarter 2012 conference call and webcast. Participating in today's call are Mike Ball, Chief Executive Officer, Hospira; Tom Werner, Senior Vice President, Finance and Chief Financial Officer; and Sumant Ramachandra, Senior Vice President and Chief Scientific Officer.

We will be making some forward-looking statements today, which are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those indicated. A discussion of these factors is included in the Risk Factors and MD&A sections in Hospira's latest annual report on Form 10-K and subsequent Form 10-Qs on file with the SEC. We undertake no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments.

If you liked this article you might like

New Lifetime High For Hospira (HSP)

Hospira (HSP) Showing Signs Of Being Strong And Under The Radar

Trade-Ideas: Hospira (HSP) Is Today's New Lifetime High Stock

10 Best S&P 500 Health Care Stocks

10 Best S&P 500 Stocks This Year